Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up · inside the Ichimoku cloud · RSI 100 (overbought) · MACD below its signal · at its 52-week high
| 0.000100 | Price now | |
| 0.000100 | R3 (classic) | −0.00% |
| 0.000100 | R2 (classic) | −0.00% |
| 0.000100 | R1 (classic) | −0.00% |
| 0.000100 | Pivot | −0.00% |
| 0.000100 | S1 (classic) | −0.00% |
| 0.000100 | S2 (classic) | −0.00% |
| 0.000100 | S3 (classic) | −0.00% |
| 0.000100 | Previous day high | −0.00% |
| 0.000100 | Previous day low | −0.00% |
| 0.000100 | Previous week high | −0.00% |
| 0.000100 | Previous week low | −0.00% |
| 0.000100 | Previous month high | −0.00% |
| 0.000100 | Previous month low | −0.00% |
| 0.000100 | 52-week high | −0.00% |
| 0.000100 | 52-week low | −0.00% |
None of the 29 investors followed here reported a position in DGEN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DGEN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for DGEN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2023 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2022 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2021 | 185.7 | -30.0 | -27.1 | -11.8 | -11.1 | -85.0 | 566.7 | -52.5 | -94.7 | 0.0 | 0.0 | 0.0 | −97.1% |
| 2020 | 0.0 | 0.0 | 900.0 | 0.0 | -90.0 | 0.0 | 900.0 | 0.0 | 0.0 | 1000.0 | 100.0 | 59.1 | +34900.0% |
| 2019 | -95.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 900.0 | 0.0 | -90.0 | −95.0% |
| 2018 | -90.0 | 900.0 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | 0.0 | 100.0 | 0.0 | 150.0 | -60.0 | −80.0% |
| 2017 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | 0.0 | 0.0 | 4900.0 | 0.0 | -80.0 | 900.0 | 0.0 | +900.0% |
| 2016 | -16.7 | 200.0 | 0.0 | -6.7 | -85.7 | -50.0 | 110.0 | -52.4 | -99.0 | 900.0 | 9900.0 | -99.0 | −98.3% |
| 2015 | -17.0 | 8.3 | -19.7 | 0.0 | -49.5 | 91.1 | -7.8 | -46.1 | 5.1 | -40.5 | 0.0 | 0.0 | −78.3% |
| 2014 | -11.0 | 12.4 | 0.0 | -50.0 | -74.0 | 457.7 | -10.3 | 53.8 | -12.5 | -14.9 | -51.7 | 284.7 | +38.5% |
| 2013 | -4.0 | 2.1 | -4.1 | 0.0 | 0.0 | -4.3 | 0.0 | -11.1 | 12.5 | -22.2 | 11.4 | -48.7 | −60.0% |
| 2012 | 33.9 | -13.3 | -38.5 | 50.0 | -33.3 | -40.0 | -21.3 | 53.4 | 37.6 | 25.3 | 0.0 | 0.0 | −10.7% |
| 2011 | 0.0 | 0.0 | -7.1 | 7.7 | 0.0 | 28.6 | -11.1 | 0.0 | 0.0 | 0.0 | -13.8 | -18.8 | −20.0% |
| 2010 | -6.2 | -19.7 | 16.3 | -24.9 | -4.9 | 4.0 | -3.8 | -14.0 | 39.5 | -16.7 | -10.0 | 55.6 | −12.5% |
| 2009 | 0.0 | -28.6 | -20.0 | 12.5 | 6.7 | 108.3 | -30.0 | -14.3 | 66.7 | -40.0 | 33.3 | 0.0 | +14.3% |
| 2008 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | -14.3 | -25.0 | -22.2 | 71.4 | -29.2 | -23.5 | 7.7 | −41.7% |
| 2007 | -11.1 | -5.0 | 2.6 | -10.3 | 8.6 | -15.8 | 3.1 | -43.9 | -45.9 | 60.0 | -25.0 | 0.0 | −73.3% |
TimeframesMixed on the daily, weekly and monthly.
under a flat 21 EMA
pulling back under the 21 EMA
pulling back under the 21 EMA
No analyst coverage for this instrument.
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1997 and is headquartered in San Mateo, California.